

1st European CAR T Cell Meeting

14th - 16th February 2019
Paris, France

Thursday, 14th February		Friday, 15th February		Saturday, 16th February			
TIME	PLENARY	TIME	PLENARY	TIME	GENERAL SESSION 1/3	PARALLEL SESSION 2/3	PARALLEL SESSION 3/3
8:30		8:30		8:30	08:30 - 09:45 PARALLEL SESSION 1/3 General session - Part 1	08:30 - 09:45 PARALLEL SESSION 2/3 Nurses session - Patient care - Part 1	08:30 - 09:45 PARALLEL SESSION 3/3 Data managers session - Data collection & LTFU Part 1
8:45		8:45		8:45	<ul style="list-style-type: none"> CAR-T cells for non immunologists: A simple description of the technology M. Hudecek (Germany) Current status of CAR-T cell development in Europe and elsewhere A. Urbano-Ispizua (Spain) The supply chain for autologous CAR-T cell from a hospital perspective C. Chabannon (France) 	<ul style="list-style-type: none"> What is driving CARs into the spotlight - The science simplified E. Vickers (United Kingdom) A CAR-T for Everything - Overview of current studies and indications Patient selection and harvesting the CAR M. Vercasson (France) 	<ul style="list-style-type: none"> The Cell Therapy Form in the EBMT registry C. Ruiz de Elvira (United Kingdom) The EMA initiative on registries E. McGrath (Spain) Specifics of LTFU for patients treated with gene therapy medicinal products
9:00		9:00	08:30 - 10:00 SCIENTIFIC SESSION Pre-clinical & clinical pipeline - Part 1				
9:15		9:15	<i>M. Hudecek (Germany)</i> <i>K. Straathof (United Kingdom)</i> <i>G. Dotti (USA)</i>				
9:30		9:30	10:00 - 10:45 KEY NOTE LECTURE C. June (USA)				
9:45		9:45		9:45	Coffee break		
10:00		10:00		10:00			
10:15		10:15		10:15	10:15 - 12:00 PARALLEL SESSION 1/3 General session - Part 2	10:15 - 12:00 PARALLEL SESSION 2/3 Nurses session - Patient care - Part 2	10:15 - 12:00 PARALLEL SESSION 3/3 Data managers session - Data collection & LTFU Part 2
10:30		10:30		10:30	<ul style="list-style-type: none"> Issues with centers selection and qualification T. Pagliuca (United Kingdom) Reimbursement issues Patient perspectives N. Bolaños (France) & B. Verhoeven (The Netherlands) 	<ul style="list-style-type: none"> Evaluation & Preparation of Pediatric Patients for CAR T-Cell Treatment D. Hutt (Israel) Ambulatory CAR; nursing assessment post Initial Episode of Care (IEC) D. Comerford (United Kingdom) The EBMT Guidelines for practice - A framework for managing Patient Care, CRS and Neurotoxicity R. Ellard (United Kingdom) & O. Stewart (United Kingdom) 	<ul style="list-style-type: none"> PASS Studies and CAR T: Regulatory requirements Example on registration From Promise to MACRO and minimalized data sets P. Ljungman (Sweden)
10:45		10:45	Coffee break				
11:00		11:00					
11:15		11:15					
11:30		11:30		11:30			
11:45		11:45	11:15 - 12:15 FLASH TALKS & ABSTRACTS Speakers to be selected from abstract submissions	11:45			
12:00		12:00	12:15 - 13:00 KEY NOTE LECTURE M. Sadelain (USA)	12:00			
12:15		12:15		12:15	Lunch		
12:30		12:30		12:30			
12:45		12:45		12:45			
13:00	12:30 - 12:45 OPENING CEREMONY • About EBMT/EHA and their activities	13:00		13:00	Satellite Symposium 4		
13:15	12:45 - 14:15 SCIENTIFIC SESSION LATEST CLINICAL DATA	13:15	Lunch	13:15			
13:30	• CD19 - ALL/Lymphoma • BCMA - Myeloma A. Garfall (USA) • CD123 - AML E. Budde (USA) • CD20 - Lymphoma C. Mackall (USA)	13:30		13:30	13:30 - 15:00 PARALLEL SESSION 1/3 General session - Part 1 - Repeat session	13:30 - 15:00 PARALLEL SESSION 2/3 Physicians session - Patient care - Part 1	13:30 - 15:00 PARALLEL SESSION 3/3 Cell collection, cell processing facilities and hospital pharmacies personnel - Mastering the supply chain - Part 1
13:45	14:15 - 15:15 SCIENTIFIC SESSION When to use CAR-T in...	13:45		13:45	<ul style="list-style-type: none"> CAR-T cells for non immunologists: A simple description of the technology M. Hudecek (Germany) Current status of CAR-T cell development in Europe and elsewhere A. Urbano-Ispizua (Spain) The supply chain for autologous CAR-T cell from a hospital perspective C. Chabannon (France) 	<ul style="list-style-type: none"> The Dutch experience for clinical implementation of CAR T cells in children and adults M. Minnema (The Netherlands) Management of CRS and neurotoxicities M. Topp (Germany) A quality system for centers administering CAR T cells: The JACIE model E. McGrath (Spain) 	<ul style="list-style-type: none"> Collection of autologous mononuclear cells H. Böinig (Germany) Processing, QC and shipment of collected cells J. Larghero (France) Point-of-care manufacturing
14:00	• CAR-T cells in acute myeloid leukemia M. Mohy (France)	14:00	Satellite Symposium 2				
14:15	• CAR-T cells in acute lymphoid leukemia A. Nagler (Israel)	14:15					
14:30	• CAR-T cells in lymphoma M.J. Kersten (The Netherlands)	14:30	14:30 - 16:00 SCIENTIFIC SESSION EMA & industry perspective on CAR-T in EU				
14:45	• CAR-T cells in multiple myeloma H. Einsele (Germany)	14:45		14:45			
15:00		15:00	• EMA M. Schüssler-Lenz (Germany) • Novartis A. Bondanza (Italy) • Janssen M. Kalos (USA) • Celgene S. Frankel (USA) • Reimbursement C. Haag (Germany)	15:00	Coffee break		
15:15		15:15		15:15			
15:30	Coffee break	15:30	16:00 - 17:00 SCIENTIFIC SESSION Clinical implementation & management	15:30	15:30 - 17:00 PARALLEL SESSION 1/3 General session - Part 2 - Repeat session	15:30 - 17:00 PARALLEL SESSION 2/3 Physicians session - Patient care - Part 2	15:30 - 17:00 PARALLEL SESSION 3/3 Cell collection, cell processing facilities and hospital pharmacies personnel - Mastering the supply chain - Part 2
15:45		15:45		15:45	<ul style="list-style-type: none"> Issues with centers selection and qualification T. Pagliuca (United Kingdom) Reimbursement issues Patient perspectives N. Bolaños (France) & B. Verhoeven (The Netherlands) 	<ul style="list-style-type: none"> Evaluation of disease response A. Nagler (Israel) Is this the end? The need for consolidation? Bridge to transplantation? CAR-T cells in treatment strategies S. Mielke (Sweden) The EBMT Registry: Fulfilling the needs of multiple stakeholders N. Kröger (Germany) 	<ul style="list-style-type: none"> Role of the pharmacist in reception, storage and delivery of CAR-T Cells. Transfer to the clinical ward and delivery of the gene therapy medicinal product Techniques for thawing cryopreserved CAR-T Cells B. Mfarrej (France) "Out-of-specification" products
16:00	15:45 - 16:30 KEY NOTE LECTURE S. Riddell (USA)	16:00	• Würzburg experience M. Hudecek (Germany) • Lille experience I. Yacoub-Agha (France) • Milan experience F. Ciceri (Italy) • Catalan experience J. Delgado (Spain) • RWE for CAR T evaluation D. Schulthess (The Netherlands)				
16:15		16:15					
16:30	16:30 - 17:30 SCIENTIFIC SESSION CAR-T in pediatrics	16:30					
16:45	• Titles to be announced A. Künkele (Germany) F. Locatelli (Italy) A. Baruchel (France) P. Bader (Germany)	16:45		16:45			
17:00		17:00	Coffee break	17:00	17:00 - 17:15 CLOSING REMARKS		
17:15		17:15		17:15			
17:30		17:30		17:30			
17:45		17:45	17:30 - 18:30 SCIENTIFIC SESSION 2 Pre-clinical & clinical pipeline - Part 1	17:45			
18:00		18:00	• TEGs J. Kuball (Germany) • Title to be announced P. Lu (China)	18:00			
18:15	Satellite Symposium	18:15		18:15			
18:30		18:30		18:30			
18:45		18:45	Satellite Symposium 3	18:45			
19:00		19:00		19:00			
19:15		19:15		19:15			
19:30	Welcome reception & poster session	19:30		19:30			
19:45		19:45		19:45			